IOVA | Iovance Biotherapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	5.68 - 6.09
52 Week Range	5.05 - 18.33
Beta	0.82
Implied Volatility	116.50%
IV Rank	80.65%
Day's Volume	10,818,757
Average Volume	7,405,791
Shares Outstanding	304,781,000
Market Cap	1,761,634,180
Sector	Healthcare
Industry	Biotechnology
IPO Date	2010-10-15

Valuation
Profitability
Growth
Health
P/E Ratio	-3.91
Forward P/E Ratio	-2.82
EPS	-1.48
1YR Price Target	21.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	557
Country	USA
Website	IOVA

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company. The company focused on the development and commercialization of cell therapies as novel cancer immunotherapy products designed to harness the power of a patient's immune system to eradicate cancer cells. Its lead pipeline candidate, LN-145, is an adoptive cell therapy using tumor-infiltrating lymphocytes to treat patients with refractory metastatic melanoma.

IOVA's peers: ABCL, ANVS, AVXL, BNTX, DMAC, IONS, PTCT, KRYS, SRPT, MDGL, CVAC, APLS, MRTX, CWBR, RAIN, OCEA, HEPA, MCRB, PBYI, PLX, RPRX, SCPH, TSVT, VERU

*Chart delayed

Analyzing fundamentals for IOVA we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see IOVA Fundamentals page.

Watching at IOVA technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, as well as bearish short-term trend. More technicals details can be found on IOVA Technicals page.